Cohen's appointment comes as the company accelerates growth and its Aurion WPT™ wireless power platform advances toward becoming the standard for implantable medical devices. BURLINGTON, Vt., Sept. 30, 2025 /PRNewswire-PRWeb/ -- Resonant Link Medical, an innovative medical technology company redefining wireless power and data transfer for implantable devices, today announced the appointment of veteran medical technology executive Raymond W. Cohen as the Chair of its Board of Directors. Cohen's appointment c ...

Core Insights - RxSight, Inc. has appointed Raymond W. Cohen to its Board of Directors, which is expected to enhance the company's growth strategy and market reach in the ophthalmic medical device sector [1][2]. Company Overview - RxSight, Inc. specializes in ophthalmic medical devices, focusing on providing customized vision solutions for patients post-cataract surgery [4]. - The company's flagship product, the RxSight® Light Adjustable Lens system, is the first commercially available intraocular lens technology that can be adjusted after surgery, allowing for tailored vision outcomes [4]. Leadership Experience - Raymond W. Cohen brings over 40 years of experience in the medical technology industry, having co-founded Axonics, Inc., which achieved over $1 billion in revenue within four years of its launch and was acquired by Boston Scientific for $3.7 billion in 2024 [2][3]. - Cohen has held various leadership roles in multiple healthcare companies, indicating a strong background in scaling medical technology businesses [3]. Strategic Vision - Cohen sees significant potential for RxSight to strengthen its position in the premium intraocular lens market and aims to support the company's growth in revenue and profits [3]. - The company aims to expand the reach of its Light Adjustable Lens system, thereby benefiting more physicians and patients [2][3].

Core Viewpoint - InspireMD, Inc. has appointed Raymond W. Cohen to its Board of Directors, bringing over 40 years of experience in medical technology to enhance the company's strategic vision and operational execution [1][2]. Company Overview - InspireMD is focused on developing the CGuard® Prime carotid stent system aimed at preventing strokes, utilizing proprietary MicroNet™ mesh technology to achieve superior acute results and long-term outcomes [6]. Leadership Experience - Raymond W. Cohen has a notable track record, having co-founded Axonics, Inc., which went public in 2018 and was acquired by Boston Scientific for $3.7 billion in November 2024 [2]. - Cohen previously served as Chairman of SoniVie Ltd., which was acquired by Boston Scientific for $600 million, and has held leadership roles in various medical technology companies [3][4]. Strategic Goals - The company is shifting its focus towards the commercial launch of the CGuard Prime stent system following its recent PMA approval, with expectations of capturing market share and delivering long-term value [2][5]. - Cohen expressed confidence in InspireMD's potential to lead the U.S. carotid stent market due to its innovative approach and commitment to clinical excellence [5].

Financial Performance - The company's reported net sales reached $5061 billion, demonstrating a 228% increase year-over-year[21] - Operational net sales grew by 216% year-over-year[14] - Organic net sales increased by 174% compared to the previous year[14] - Reported earnings per share (EPS) stood at $053, compared to $022 in Q2 2024[18] - Adjusted EPS was $075, up from $062 in Q2 2024[18] - The company's free cash flow reached $1129 million in Q2 2025, compared to $660 million in Q2 2024[35] Segment Performance - MedSurg segment reported net sales of $1716 billion, a 157% increase year-over-year[22] - Cardiovascular segment reported net sales of $3345 billion, a 268% increase year-over-year[25] - Cardiology segment net sales increased by 293% to $2647 billion[27] - Electrophysiology (EP) net sales surged by 961% to $840 million[27] Guidance - The company projects Q3 2025 reported net sales growth of 17%-19% and organic net sales growth of 12%-14%[18] - Q3 2025 reported EPS is expected to be $044-$046, with adjusted EPS of $070-$072[18] - For the full year 2025, the company anticipates reported net sales growth of 18%-19% and organic net sales growth of 14%-15%[18] - Full year 2025 reported EPS is projected to be $189-$193, with adjusted EPS of $295-$299[18]

招商通知 第三届全球手术机器人大会 第二届全球医疗科技大会 心未来 这笔 资金将用于推进核心产品 主动脉弓压力感受器植入物 Barostent™ 的研发及临床前验证 ，为 FDA 批准人体临床试验做准备，进一步巩固其在高血压治疗植入物领域的技术优势。 # 研究背景 高血压 是全球患病率最高的慢性病之一， 与动脉粥样硬化性心脏病、心力衰竭、卒中等心脑血管疾病密 切相关， 目前全球高血压患者 超过 10 亿人 。 根据 WHO 发布的数据显示，从 1990 年到 2019 年，全球 30~79 岁成年高血压患者数量翻倍。 ▲ 血压测量及高血压诊断流程 源自 《中国高血压防治指南（2024年修订版）》 近日，专注于治疗高血压的临床前阶段医疗器械公司 Archimedes Vascular 宣布完成了由Sherpa Healthcare Partners领投的220万美元（ 约合人民币1576万 ） A轮融资 ，并任命 Raymond W. Cohen 担任其董事会主席。 目前，高血压治疗以生活方式干预和药物治疗为主，但由于生活方式改善难以坚持，部分患者药物依从性 欠佳、对药物的不良反应存在顾虑，以及部分患者对降压药 ...

Core Viewpoint - Boston Scientific (BSX) has demonstrated strong performance with a 42.4% increase in share price over the past year, significantly outperforming the industry growth of 8.5% and the S&P 500's 10.6% increase, indicating solid fundamentals and growth opportunities for investors [1] Company Overview - Boston Scientific manufactures medical devices and products for various interventional medical specialties globally, having reorganized its operational structure into two reportable segments: MedSurg and Cardiovascular [2][3] Segment Performance - The Cardiovascular segment includes the Cardiology division and Peripheral Interventions, while the MedSurg group consists of Endoscopy, Urology, and Neuromodulation [3] Growth Drivers - The upward trend in BSX's share price is driven by the strong performance of the WATCHMAN left atrial appendage closure device, with the next-generation WATCHMAN FLX and FLX Pro capturing significant market share [4] - The launch of the FARAPULSE Pulsed Field Ablation System and commercial excellence across various businesses are also contributing to share price growth, supported by a solid fourth-quarter performance and increasing revenues from both reportable segments [5] Strategic Acquisitions - Investors are optimistic about BSX's strategic acquisitions in 2024, including Axonics, Inc., Intera Oncology Inc., and Cortex, Inc., which are expected to bolster the company's market position [6][7] International Expansion - Boston Scientific's international expansion remains strong, with emerging markets showing robust growth despite geopolitical challenges, and the launch of the next-generation accurate Prime Valve in Europe [8] - The FARAPULSE uptake in the EMEA region and strong growth in the Asia Pacific, particularly in China, Japan, Australia, and New Zealand, contributed to revenue increases of 10.8% in EMEA and 11.1% in Asia Pacific during the fourth quarter [9] Financial Performance - For the fourth quarter of 2024, BSX reported a 27.9% rise in the cost of products sold, leading to a 138-basis points contraction in gross margin due to macroeconomic headwinds and supply chain disruptions [10] - The company is also exposed to currency fluctuations, with expectations of a 100-basis point headwind from foreign exchange on revenues for 2025 [11] Earnings Estimates - The Zacks Consensus Estimate for BSX's 2025 EPS has increased by 0.7% to $2.85, with an earnings yield of 2.9%, outperforming the industry's 1.2% [12]

2025年2月5日， 波士顿科学 公布了 2024年第四季度及全年业绩 ， 第四季度销售额 45.61亿美元（约合332亿人民币） ，同比增长22.4%；全年总营收 167.47亿美元（约合1220亿人民币） ， 同比 增长17.6%。 # 财报亮点 第四季度的净销售额 为45.61亿美元 ，同比增长22.4%（报告）、23.1%（运营）和19.5%（有机）；每股收益（EPS）为0.38美元，同比增长11.8%，调整后 为0.70美元，同比增长27.3%； 毛利率为67.9%，同比下降130个基点；调整后为70.6%，同比增长20个基点；营业利润率为14.8%，同比下降90个基点；调整 后为27.4%，同比增长80个基点。 全年净销售额为167.47亿美元 ，同比增长17.6%（报告）、18.5%（运营）和16.4%（有机）；每股收益（EPS）为1.25美元，同比增长20.0%，调整后为2.51 美元，同比增长100.0%；毛利率为68.6%，同比下降90个基点；调整后为70.3%，同比下降40个基点；营业利润率为15.5%，同比下降100个基点，调整后为 27.0%，同比增长70个基点。 | Q4 & FY ...